Read + Share
Amedeo Smart
Independent Medical Education
Schulman KA, Greicius MD, Richman B. Will CMS Find Aducanumab Reasonable and Necessary for Alzheimer Disease After FDA Approval? JAMA 2021 Jul 19. pii: 2782333. doi: 10.1001/jama.2021.11768.PMID: 34279572
Email
LinkedIn
Facebook
Twitter
Privacy Policy